The Patent Landscape Analysis of Skin Bioinks for 3D Bioprinting
November 2022
in “
Journal of Investigative Dermatology
”
New to collagen? There is a guide in the encyclopedia. Read the guide → 
Studysummary This review analyzes granted patents for skin bioinks for 3D skin bioprinting from 2017 to 2022 and reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study analyzed granted patents for skin bioinks intended for 3D skin bioprinting from 2017 to 2022. The search yielded 550 patents, of which 45 were included in the analysis. The patent applications were filed by nine countries, with South Korea (20) and China (15) filing the most. The most common materials used in a hydrogel composition were collagen (13) and gelatin (8). The skin bioinks were intended for use in vivo (24), in vitro (12), or both (5). The study concludes that 3D skin bioprinting is expected to rapidly expand in the near future and could be beneficial for a range of conditions, including chronic wounds, burns, and skin cancers. Skin bioinks could also be used for in vitro cosmetics, drug, and toxicity testing.
